Survival in Hodgkin’s disease patients – Report of 25 years of experience at the Milan Cancer Institute

De Vita, 1970, Combination chemotherapy in the treatment of Hodgkin’s disease, Ann Intern Med, 73, 881, 10.7326/0003-4819-73-6-881 De Vita VT. A selective history of the therapy of Hodgkin’s disease. Br J Haematol 2003, 122, 718–27 Bonadonna, 1975, Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP, Cancer, 36, 252, 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7 Bonadonna, 1982, ABVD chemotherapy in the treatment of Hodgkin’s disease, Cancer Treat Rev, 9, 21, 10.1016/S0305-7372(82)80003-0 Santoro, 1987, Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease. Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy, J Clin Oncol, 5, 27, 10.1200/JCO.1987.5.1.27 Bonadonna, 1986, Alternating non-cross-resistant combination chemotherapy or mechlorethamine, vincristine, procarbazine, and prednisone in stage IV Hodgkin’s disease. A report of 8-year results, Ann Intern Med, 104, 739, 10.7326/0003-4819-104-6-739 Viviani, 1996, Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease, ten year results, J Clin Oncol, 14, 1421, 10.1200/JCO.1996.14.5.1421 Santoro, 1986, CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin’s disease, Semin Oncol, 13, 23 Gianni, 1991, Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin’s disease, Ann Oncol, 2, 645, 10.1093/oxfordjournals.annonc.a058043 Kaplan, 1958, Non parametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Peto, 1972, Asymptotically efficient rank invariant test procedures, J R Stat Soc A, 135, 185, 10.2307/2344317 Marubini, 1995 Bonadonna, 1982, Chemotherapy strategies to improve the control of Hodgkin’s disease. The Richard and Hinda Rosenthal Foundation Memorial lecture, Cancer Res, 42, 4309 Canellos, 1992, Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD, New Eng J Med, 327, 1478, 10.1056/NEJM199211193272102 Duggan, 2003, Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease, report of an intergroup trial, J Clin Oncol, 21, 607, 10.1200/JCO.2003.12.086 van Leeuwen, 1994, Second cancer risk following Hodgkin’s disease: a 20 year follow-up study, J Clin Oncol, 12, 312, 10.1200/JCO.1994.12.2.312 Dores, 2002, Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years, J Clin Oncol, 20, 3484, 10.1200/JCO.2002.09.038 Jostings, 2003, Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s lymphoma study group, J Clin Oncol, 21, 3440, 10.1200/JCO.2003.07.160 Behringer, 2004, Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s lymphoma study group, Ann Oncol, 15, 1079, 10.1093/annonc/mdh273 Ng, 2002, Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger, J Clin Oncol, 20, 2101, 10.1200/JCO.2002.08.021 Aleman, 2003, Long-term cause-specific mortality of patients treated for Hodgkin’s disease, J Clin Oncol, 21, 3431, 10.1200/JCO.2003.07.131 Connors, 2003, Hodgkin’s disease: the hazards of success, J Clin Oncol, 21, 3384, 10.1200/JCO.2003.07.001 Diehl, 2003, Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease, New Eng J Med, 348, 2386, 10.1056/NEJMoa022473 Horning, 2002, Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial, J Clin Oncol, 20, 630, 10.1200/JCO.20.3.630